News
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD The study will enrol up to 36 adult subjects at multiple sites in North America Study strengthens NST’s position as a multi-asset, clinical stage company Amsterdam, The Netherlands,...
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting
Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy − ICONA study assessed the safety, tolerability and efficacy of Icosabutate, a novel, dual FFAR1/FFAR4 (GPR40/GPR120) agonist in NASH patients with F1-F3...
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
- RPD designation underscores critical need for novel therapies to address IFALD Amsterdam, The Netherlands, October 17 — NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis...
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes
- NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform - Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected in Q1 2023 - Phase 1 trial with SEFA-1024 (being developed...
NorthSea Therapeutics appoints Morris J. Birnbaum to the Board
Former Pfizer Internal Medicine CSO joins the Boardas an independent board member Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a biotech company developing novel and innovative strategies for the treatment of...
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated liver disease (IFALD) SEFA-6179 is NST’s third programme to enter...
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
Financing co-led by Ysios Capital and Forbion Growth Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and...
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severityResults presented at the AASLD Liver Meeting Digital Experience™ 2021 Significant decreases in key markers of...
Positive Phase 2b ICONA interim results for icosabutate in NASH patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent,...
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development...